Synribo omacetaxine mepesuccinate regulatory update

FDA granted full approval to Teva's Synribo omacetaxine mepesuccinate to treat chronic or accelerated phase chronic myelogenous leukemia (CML) in adults with resistance and/or intolerance to >=2 tyros...